Introduction
The c-Myc protein plays an important role in cell proliferation by transactivating target genes such as Cdc25 phosphatase essential for cell cycle progression (Galaktionov et al., 1996) . Presumably due to the activity for cell proliferation, deregulated expression of c-Myc induces oncogenesis (Adams et al., 1985; DallaFavera et al., 1982) . In contrast, overexpression of cMyc induces apoptosis of ®broblasts upon serum deprivation or treatment with cytokines or chemicals carrying anti-proliferative activity (Evan et al., 1992) . Moreover, c-Myc enhances apoptosis of various cell types induced by various stimuli, such as irradiation (Chen et al., 1994) , tumor necrosis factor (TNF) (Klefstrom et al., 1994) , growth factor deprivation (Askew et al., 1991) and anti-cancer drugs (Dong et al., 1997) . Apoptosis by deregulated c-Myc expression may be involved in maintenance of homeostasis by counteracting its oncogenic activity. Indeed, expression of Bcl-2 carrying anti-apoptotic function markedly enhances the oncogenesis by deregulated c-Myc expression (Strasser et al., 1990) .
Overexpression of c-Myc enhances expression of the tumor suppressor gene p53 (Hermeking and Eick, 1994; Reisman et al., 1993) . In embryonic ®broblasts obtained from p53-de®cient mice, deregulated c-Myc expression fails to induce apoptosis (Hermeking and Eick, 1994; Wagner et al., 1994) , indicating that p53 is involved in c-Myc-mediated apoptosis. In contrast, lines of evidence suggest that a p53-independent pathway is also involved in c-Myc-induced apoptosis. Indeed, renal tubular epithelial cells of p53-de®cient mice undergo apoptosis in the presence of deregulated c-Myc expression (Trudel et al., 1997) , indicating that c-Myc-mediated apoptosis does not require p53 in renal tubular cells. Moreover, deregulated c-Myc induces apoptosis in epithelial cells and Rat1 fibroblasts when p53-mediated transactivation is almost completely abrogated by a dominant negative form of p53 or the SV-40 T antigen that inactivates p53 by physical association (Klefstrom et al., 1994; Lenahan and Ozer, 1996; Sakamuro et al., 1995) . In epithelial cells and Rat1 cells, p53-mediated transactivation appears dispensable in c-Myc-induced apoptosis, although involvement of a transactivation-independent pathway (Caelles et al., 1994; Haupt et al., 1995; Wang et al., 1996) is not yet ruled out. Regardless of whether c-Myc-induced apoptosis is induced by serum deprivation or treatment with TNF, Rat1 cells do not require p53-mediated transactivation and embryonic fibroblasts require p53 for apoptosis (Hermeking and Eick, 1994; Klefstrom et al., 1997; Wagner et al., 1994) . Thus, requirement of p53 or its transactivation for c-Myc-induced apoptosis may depend on cell types but not types of apoptotic stimulation. However, little is known about what induces pathways independent of p53 or its transactivation for c-Myc-induced apoptosis in certain cell types.
Interaction with antigens appears to trigger activation and clonal expansion of B cells. However, antigen receptor of B cells (BCR) is also capable of transmitting a negative signal, resulting in functional inactivation or apoptosis of B cells (Goodnow, 1992) . Such negative signaling via BCR may play a role in maintaining the normal immune system by inactivating or deleting self-reactive B cells upon interaction with self-antigens. B cell lines such as WEHI-231 undergo apoptosis when BCR is ligated (Benhamou et al., 1990; Hasbold and Klaus, 1990) . In WEHI-231 cells, BCR ligation markedly enhances the level of c-Myc within 1 h (McCormack et al., 1984) . Subsequently, the level decreases and becomes undetectable after 8 h. Recently, Wu et al. (1996a) demonstrated that WEHI-231 transfectants stably expressing c-Myc fail to undergo apoptosis by BCR ligation, suggesting that overexpression of c-Myc fails to enhance but rather blocks BCRmediated apoptosis. Down-modulation of c-Myc by BCR ligation may thus be responsible for BCRmediated apoptosis. This conclusion is also supported by the ®nding that treatment with TGF-b or inhibitor of I-kB phosphorylation down-modulates the c-Myc level, followed by apoptosis in WEHI-231 cells (Fischer et al., 1994; Warner et al., 1992; Wu et al., 1996b) . Thus, apoptosis is induced by down-modulation of cMyc in WEHI-231 but by deregulated c-Myc expression in many other cell types such as ®broblasts and epithelial cells. Therefore, c-Myc is suggested to play a distinct role in WEHI-231 from other cell types.
Although the ®nding on WEHI-231 transfectants constitutively expressing c-Myc is the key evidence suggesting that deregulated c-Myc expression induces survival in WEHI-231 cells, this transfection may select variant cells resistant to apoptosis. Granted that c-Myc carries pro-apoptotic function in B cells as well, WEHI-231 transfected with the expression plasmid may undergo apoptosis by the expression of c-Myc. Only variant cells carrying defects in apoptosis may survive the selection. Those variant cells may highly express c-Myc but fail to undergo apoptosis as described by Wu et al. (1996a) . To exclude the generation of variant cells resistant to apoptosis, we transfect WEHI-231 cells with the plasmid coding for a chimera consisting of c-Myc and hormone binding domain of the estrogen receptor (ER) (Eilers et al., 1989) . The MycER chimera is transcriptionally inactive in the absence of estrogen, but is able to transactivate the target genes for c-Myc in the presence of estradiol. By using this induction system, we demonstrate that deregulated c-Myc expression induces apoptosis by itself in a p53-dependent manner in WEHI-231 cells. In contrast, c-Myc markedly enhances apoptosis upon BCR crosslinking even when p53-mediated transactivation is completely inactivated by a dominant negative form of p53. These results strongly suggest that BCR signaling activates a p53-independent pathway for cMyc-induced apoptosis.
Results
Expression of c-Myc induces apoptosis of WEHI-231 in the absence of BCR crosslinking and enhances BCR-mediated apoptosis
To ask whether expression of c-Myc induces apoptosis, we transfected WEHI-231.5 cells with an expression plasmid coding for the MycER chimeric molecule. When the expression of MycER was assessed by Western blotting using anti-ER antibody, the level of MycER was very low in nuclear extracts from the MycER transfectants in the absence of b-estradiol, whereas the treatment with 0.1 mM b-estradiol markedly increased the amount of nuclear MycER ( Figure   1a ) and the same number of cells of two independently obtained WEHI-231.5 MycER transfectants (W-MycER2 and W-MycER4) were cultured in 10 ml of phenol red-free medium with or without 0.1 mM b-estradiol (E2). After 6 h, cells were collected. Nuclei were then prepared and lysed in 30 ml of phospholysis buer. Nuclear extracts (100 mg) were separated by SDS ± PAGE under reducing conditions. Expression of MycER was detected by Western blotting using anti-human estrogen receptor a chain Ab. To ask whether p53 is essential for apoptosis of WEHI-231 induced by c-Myc, we transfected WMycER cells with the expression plasmid for the dominant negative form of p53 (p53DD) containing the oligomerization domain but lacking the DNA binding domain (Shaulian et al., 1992) . We chose two transfectants W-MycER-p53DD11 and W-MycERp53DD21 for further analysis. When we examined the level of p53 in WEHI-231 transfectants by 4 ) were cultured in 1.0 ml of phenol red-free medium with or without 0.1 mM b-estradiol (E2) for 48 h. Alternatively, the same number of W-MycER2 cells were cultured in 1.0 ml of medium with 0.1 mM b-estradiol (E2) for 24 h, followed by addition of anti-IgM Ab to the ®nal concentration of 10 mg/ml and culturing for another 24 h. Cells were then harvested, lysed in 0.2 ml of 0.15% Triton-X in PBS and incubated with 5 mg/ml of RNase A and 50 mg/ml of propidium iodide (PI). DNA contents of the nuclei were analysed by FACSCalibur Although deregulated c-Myc expression has been shown to up-regulate p53 expression in ®broblasts (Hermeking and Eick, 1994; Reisman et al., 1993) , cMyc may not signi®cantly transactivate p53 in B cells. To ask whether p53DD blocks transactivation by p53, we tested the DNA binding capacity of p53 in W-MycER cells and W-MycER-p53DD cells either untreated or treated with X-irradiation of 1000 R. The DNA binding capacity of p53 was almost undetectable in W-MycER-p53DD11 even when the level of endogenous p53 is up-regulated by Xirradiation (Figure 5a ). In W-MycER-p53DD21, DNA binding of p53 was markedly reduced. Transactivation by p53 thus appeared to be markedly inhibited in W-MycER-p53DD cells. This conclusion was also supported by Western blotting for the p21
Cip1 protein, the product of a p53-inducible gene. Indeed, X-irradiation induced expression of p21 Cip1 in W-MycER cells but not W-MycERp53DD11 nor W-MycER-p53DD21 cells ( Figure  5b ), indicating that p53DD blocks expression of the p53-inducible gene. Taken together, DNA binding and transactivation by p53 are almost completely suppressed in W-MycER-p53DD cells even when p53 is up-regulated by X-irradiation. Since BCR crosslinking does not up-regulate p53, the transcriptional activity of p53 appears to be abrogated almost completely in W-MycER-p53DD cells even in the presence of BCR signaling.
As is the case for W-MycER cells, both W-MycERp53DD11 and W-MycER-p53DD21 cells showed a small number of dead cells in the absence of b-estradiol (Figure 6a ). When treated with b-estradiol, the number of dead cells did not change in both of the W-MycERp53DD transfectants, whereas around a half of WMycER cells died by the same treatment. This indicates that WEHI-231 cells require p53 for apoptosis induced by c-Myc alone. In contrast, almost all the W-MycERp53DD cells died by the treatment with anti-IgM and b-estradiol, as is the case for W-MycER cells, whereas neither parent WEHI-231.5 cells nor WEHI-231.5 transfected with p53DD alone (W-p53DD) died by the same treatment (Figure 6b ). This strongly suggests that p53-mediated transactivation is not essential for rapid apoptosis of WEHI-231 induced by deregulated c-Myc expression in the presence of BCR signaling. Taken together, deregulated expression of c-Myc may require p53-mediated transactivation for apoptosis in the absence of BCR signaling but not in the presence of BCR signaling. BCR signaling is thus likely to activate a p53-independent pathway of c-Myc-induced apoptosis. ) and the same number of two independently obtained W-MycER transfectants expressing a dominant negative form of p53 (W-MycER-p53DD11 and WMycER-p53DD21) were exposed to X-ray (1000 R). Either irradiated or untreated cells (5. 0610 7 ) were then homogenized and nuclei were incubated with extraction buer. The nuclear extracts were mixed with a 32 P-labeled target DNA of p53, followed by immunoprecipitation with goat anti-p53 Ab. Labeled DNA in the precipitates were extracted and electrophoresed on a 5% native polyacrylamide gel. The radioactivity of the labeled DNA was quanti®ed by an image analyzer. Representative data of two experiments are shown. (b) p53DD inhibits expression of p21
Cip1 induced by X-irradiation. W-MycER4 cells (3. 0610 6 ) and the same number of W-MycER-p53DD11 and W-MycERp53DD21 cells were exposed to 3000 R X-ray. Irradiated or untreated cells were cultured in medium for 12 h, and then lysed in 50 ml of phospholysis buer. Proteins (80 mg) were separated by SDS ± PAGE under reducing conditions, followed by Western blotting using anti-p21
Cip1 Ab. The blot was reprobed with antitubulin Ab to ensure equal loading of the immunoblot. The band for p21 is indicated by an arrow. Representative data of three experiments are shown Figure 6 Eect of a dominant negative form of p53 on cell death of WEHI-231 induced by c-Myc. WEHI-231.5 cells (1.0610 4 ) and the same number of WEHI-231.5 transfectants expressing p53DD alone (W-p53DD), MycER alone (W-MycER2 and 4) and those expressing both MycER and p53DD (W-MycER-p53DD11 and 21) were cultured in 0.2 ml of phenol red-free medium with or without 0.1 mM b-estradiol (E2) (a). Alternatively, cells were cultured in 0.2 ml of phenol red-free medium with 0.1 mM bestradiol in the presence or absence of anti-IgM Ab as in the legend to Figure 3a (b) . After 48 h, numbers of alive and dead cells were counted by trypan blue exclusion, and percentages of dead cells were calculated. The data represent mean+s.d. of triplicate cultures. Representative data of three experiments are shown c-Myc-induced apoptosis of B lymphocytes H Hagiyama et al of its transactivation capacity (Caelles et al., 1994; Haupt et al., 1995; Wang et al., 1996) . However, overexpression of particular alleles of transactivationde®cient p53 is required for apoptosis and the apoptosis is much reduced than that induced by wild type p53 (Haupt et al., 1995) . We show that BCR ligation fails to up-regulate the level of p53 in WEHI-231 p53DD transfectants and that BCRcrosslinked WEHI-231 transfectants eciently undergo c-Myc-induced apoptosis even in the absence of p53-mediated transactivation. It is thus unlikely that the transactivation-independent as well as -dependent apoptotic pathway of p53 is involved in c-Mycinduced apoptosis of BCR-crosslinked WEHI-231. Taken together, p53 may not be involved in c-Mycinduced apoptosis of WEHI-231 in the presence of BCR signaling. In contrast, c-Myc-induced apoptosis of WEHI-231 in the absence of BCR signaling requires p53, as deregulated expression of c-Myc alone induces apoptosis in untransfected WEHI-231 but not in WEHI-231 p53DD transfectants. BCR ligation thus most likely activates a p53-independent pathway of c-Myc-induced apoptosis.
Two lines of evidence have suggested that upregulation of c-Myc blocks the BCR-mediated apoptosis, which is inconsistent with our results showing that overexpression of c-Myc enhances apoptosis of WEHI-231. First, Fischer et al. (1994) have demonstrated that treatment of WEHI-231 with antisense oligonucleotides unexpectedly blocks both down-modulation of c-Myc and apoptosis of BCRcrosslinked WEHI-231. Second, Wu et al. (1996a) have demonstrated that WEHI-231 transfectants constitutively expressing c-Myc fail to undergo apoptosis upon BCR crosslinking. However, oligonucleotides carrying unmethylated CpG nucleotides have been shown to activate B cells (Krieg et al., 1995) and block BCRmediated apoptosis of WEHI-231 (Yi et al., 1996) . Since antisense oligonucleotides that Fischer et al. (1994) have utilized contain unmethylated CpG, the oligonucleotides abrogate BCR-mediated negative signaling presumably due to stimulation by unmethylated CpG sequences, resulting in restoration of the cMyc level and abrogation of apoptosis. Furthermore, we demonstrate here that apoptosis is induced by deregulated c-Myc expression alone in WEHI-231. Thus, transfection with a plasmid conferring stable expression of c-Myc may induce apoptosis by itself, and only variant cells resistant to apoptosis may survive. This could be the reason why the c-Myc transfectants obtained by Wu et al. (1996a) show resistance to BCR-mediated apoptosis. To avoid obtaining variant cells resistant to apoptosis, we have kept exogenous c-Myc inactive during transfection and selection, and activated c-Myc in the transfectants by b-estradiol using the MycER chimera. Moreover, we have excluded the possibility that c-Myc activity is down-modulated due to degradation or inactivation of estradiol during the culture, resulting in apoptosis. Indeed, addition of estradiol every 12 h also markedly enhances BCR-mediated apoptosis (Figure 3b) . Thus, deregulated expression of c-Myc most likely enhances but not abrogates BCR-mediated apoptosis of WEHI-231 cells.
BCR crosslinking induces a biphasic change in cMyc expression in WEHI-231 cells. The level of cMyc is markedly enhanced within 1 h and then gradually decreases (McCormack et al., 1984) . After 8 h, the level becomes far below that of unstimulated cells. Since overexpression of c-Myc enhances BCRmediated apoptosis of WEHI-231, transient upregulation of c-Myc by BCR-ligation could be involved in BCR-mediated apoptosis. This is also supported by the ®nding by Scott et al. (1996) that treatment with antisense oligonucleotides for c-myc reduces the c-Myc level and blocks BCR-mediated apoptosis in primary B cells. c-Myc may thus induce transcription of the gene(s) involved in apoptosis, although cells die after the c-Myc level is downmodulated. The c-Myc induced gene(s) may trigger an apoptotic cascade taking more than 10 h or require for apoptosis co-existence of some other genes expressed after c-Myc is down-modulated. In contrast, apoptosis of WEHI-231 induced by TGF-b or an inhibitor of I-kB phosphorylation also associates with down-modulation of c-Myc (Fischer et al., 1994; Warner et al., 1992; Wu et al., 1996b) . Thus, down-modulation of c-Myc in the late phase of BCR-mediated apoptosis might also play a role in the induction of apoptosis. However, the downmodulation of c-Myc is not essential for BCRmediated apoptosis, as deregulated c-Myc expression fails to block but rather enhances BCR-mediated apoptosis.
Embryonic ®broblasts with deregulated c-Myc expression from wild type but not p53-de®cient mice have been shown to undergo apoptosis regardless of whether apoptosis is induced by serum deprivation or treatment with TNF together with deregulated c-Myc expression (Hermeking and Eick, 1994; Klefstrom et al., 1997; Wagner et al., 1994) , indicating that c-Mycinduced apoptosis requires p53 in embryonic fibroblasts. In contrast, transgenic renal tubular cells undergo apoptosis by deregulated c-Myc in p53-de®cient mice clearly indicates that a p53-independent pathway is involved in c-Myc-induced apoptosis (Trudel et al., 1997) . Moreover, Rat1 ®broblasts overexpressing c-Myc undergo apoptosis in the absence of p53-mediated transactivation upon serum deprivation or treatment with TNF (Klefstrom et al., 1997; Lenahan and Ozer, 1996) . These ®ndings suggest that requirement of p53 for c-Myc-induced apoptosis depends on cell types or cell lines but not the stimuli inducing apoptosis together with deregulated c-Myc expression such as serum deprivation or TNF. However, we show here that c-Myc-induced apoptosis requires p53 in WEHI-231 in the absence but not presence of BCR signaling, strongly suggesting that the p53-independent pathway can be activated by transmembrane signals such as a signal via BCR. Rat1 cells might have acquired such a pathway by yet unknown signals during their dierentiation or establishment. Future studies will elucidate the molecular mechanisms for activation of the p53-independent pathway of c-Myc-induced apoptosis. Since c-Myc-induced apoptosis is suggested to counteract to its oncogenic activities (Evan and Littlewood, 1993) , the elucidation of the mechanisms for c-Myc-induced apoptosis may enhance our understanding of the mechanisms for oncogenesis and the development of new therapeutic strategies for cancers in which c-Myc expression is enhanced. 
Materials and methods

Cell culture
WEHI-231.5 is a subclone of WEHI-231 cells obtained in our laboratory. WEHI-231.5 and its transfectants were cultured in RPMI-1640 medium supplemented with 10% FCS, 50 mM 2-mercaptoethanol and 2 mM L-glutamine. For induction of apoptosis, either 1.0 or 5.0610 4 cells were cultured in 0.2 or 1.0 ml of phenol red-free medium, respectively, with 0.1 mM b-estradiol, 10 mg/ml of F (ab') 2 fragments of anity puri®ed goat anti-mouse IgM Ab (Cappel, Durham, NC, USA) or both. After 24 to 48 h, cells were collected, and numbers of alive and dead cells were counted by trypan blue exclusion. For detection of cells containing hypodiploid nuclei characteristic for apoptosis, cells were suspended in 0.2 ml of 0.15% Triton-X in PBS, and mixed with 0.2 ml of 10 mg/ ml RNase A and 20 ml of 1 mg/ml propidium iodide. Cells were then analysed by FACSCalibur 1 (Becton Dickinson, San Jose, CA, USA).
Western blotting
Cells (1 ± 30610 5 ) were lysed in 10 ± 50 ml of phospholysis buer (1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 10 mM sodium phosphate pH 7.5, 0.1 M NaCl). Alternatively, 3610 6 nuclei were prepared using a homogenizer, and lysed in 30 ml of phospholysis buer. Proteins were separated by SDS ± PAGE under reducing conditions. Western blotting was done using antibodies speci®c for c-Myc (9E10), p53 (M-19, Santa Cruz Biotechnology, Santa Cruz, CA, USA), p21
Cip1 (C-19, Santa Cruz Biotechnology), tubulin (TUB 2.1, Seikagaku Co., Tokyo, Japan) or the human estrogen receptor a chain (HC-20, Santa Cruz Biotechnology).
